Compare McCormick & Company, Incorporated (MKC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs ResMed Inc. — how do they compare? McCormick & Company, Incorporated trades at $51.5 (market cap $13.90B), while ResMed Inc. trades at $219.5 (market cap $31.73B). The key difference: ResMed Inc. is far larger — about 2.3× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| MKC | RMD | |
|---|---|---|
Market Cap | $13.90B | $31.73B |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $283.28 |
52-Week Low | $45.60 | $182.82 |
Enterprise Value | $18.50B | $31.08B |
Dividend Yield | 3.73% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $51.90, down 0.35% with a bearish technical signal. The stock shows strong fundamentals with a low P/E of 8.64, robust 21.91% net margin, and consistent revenue growth to $6.84B in 2025. Recent Q1 2026 earnings beat expectations, while analyst consensus is mixed with 36.67% buy ratings. The pending Unilever merger and upcoming Q3 2026 earnings on October 1, 2026, are key catalysts.
MKC presents a value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term pressure. The Unilever deal integration and margin expansion potential support long-term growth, but execution risks and competitive pressures remain concerns. Current price sits near the analyst low target of $52.00, offering limited downside protection.
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
